CPAP Myths vs Facts (UK Edition): Clearing Up the Most Common Misconceptions

CPAP is not addictive in any pharmacological or psychological sense. You do not develop a chemical dependence on pressurised air. What does happen is that when you use CPAP effectively and your sleep improves, stopping CPAP restores your original sleep apnoea because CPAP treats the condition during sleep but does not cure the underlying anatomy that causes it. Returning to poor sleep and the health risks of untreated OSA when you stop is not withdrawal from an addiction; it is the natural return of the condition CPAP was keeping at bay. The distinction matters because addiction is a reason to avoid something, whereas dependency on a necessary ongoing treatment is simply how many chronic conditions work just as needing glasses every day is not an addiction to lenses.

Excess body weight is a significant risk factor for OSA, and meaningful weight loss does reduce OSA severity in many people sometimes substantially. However, approximately 30% of OSA cases occur in people of normal weight, driven by anatomy rather than weight. Even in weight-related OSA, the degree of improvement is unpredictable: some patients see dramatic resolution, others see modest improvement, and a proportion find that their anatomy-related component persists regardless of weight change. The critical additional point is that untreated OSA makes weight loss harder, not easier poor sleep disrupts the appetite-regulating hormones leptin and ghrelin, increases cravings for high-calorie food, and reduces motivation for exercise. For most people, starting CPAP and losing weight simultaneously is the best approach not sequencing them, with OSA waiting while weight loss is attempted.

Obstructive sleep apnoea is not defined by snoring it is defined by repeated collapse of the upper airway during sleep, producing breathing interruptions that reduce oxygen levels and fragment sleep. Many OSA patients do not snore loudly; some do not snore at all. Conversely, not snoring on a given night does not mean the apnoea events have stopped they occur in silence as well as with sound. CPAP is prescribed based on the number and severity of breathing events, not on the presence of snoring. Skipping CPAP on nights when you believe you will not snore means exposing yourself to the same apnoea events without the protection of therapy.

The anatomical and physiological factors that produce OSA airway structure, muscle tone during sleep, body weight distribution around the neck and throat do not self-correct over time in the absence of a specific intervention. Without meaningful weight loss, surgical correction of a structural contributor, or significant lifestyle change, the severity of OSA at a follow-up study is typically comparable to or worse than the original diagnosis because most of the risk factors are either stable (anatomy) or tend to worsen with age (muscle tone, weight). If a long gap exists between your original diagnosis and now, this is more likely to mean your untreated OSA has continued for longer, not that it has resolved.

The ResMed AirSense 11 is approximately the size of a large paperback book and operates at around 25–27 dB quieter than a whispered conversation. The Fisher & Paykel SleepStyle is similarly compact. Travel CPAP devices such as the ResMed AirMini reduce the footprint further still to roughly the size of a smartphone. Current-generation machines include heated humidifiers, Bluetooth connectivity, smartphone apps, and auto-adjusting algorithms that bear very little resemblance to the bulky, fixed-pressure machines of the early 2000s. If your impression of CPAP comes from something you saw in a hospital ward or heard about years ago, the current devices are a significant revision of that image.

Sleep debt accumulated over months or years of untreated OSA does not resolve in a few nights. The first one to three weeks of CPAP often feel more tiring rather than less, because the adjustment to the mask and the new sensations of pressurised air can itself be disruptive. Most patients begin to notice meaningful improvement in energy and alertness between weeks three and six, with the most substantial improvement often occurring in weeks six through twelve as accumulated sleep debt clears and sleep architecture normalises. The patients who report that CPAP "didn't work" most often abandoned therapy in the first two to three weeks  precisely the window before the main benefit is typically felt. Clinical adherence programmes specifically target this period because the drop-off rate without support is high and the missed opportunity is significant.

All major current-generation CPAP devices (ResMed AirSense 10 and 11, Philips DreamStation 2, Fisher & Paykel SleepStyle) are universal voltage (100–240V, 50/60Hz) and work with a local plug adapter in any country. Most fit comfortably in cabin luggage and are specifically listed as permitted medical devices by UK Civil Aviation Authority (CAA) guidance you do not need to put them in the hold. Airlines cannot charge for CPAP equipment as carry-on if it is medically necessary. Dedicated travel CPAP devices (ResMed AirMini, Philips DreamStation Go) reduce size and weight further for frequent travellers. Bottled still water is an acceptable substitute for distilled water in the humidifier abroad. A doctor's letter documenting your CPAP prescription is a useful travel document but is not universally required.

CPAP delivers positive airway pressure regardless of your sleep position. There is no requirement to sleep on your back and for most OSA patients, sleeping on your side (lateral position) actually reduces the severity of airway collapse, meaning your AutoCPAP device needs to work less hard. Side-sleeping is generally encouraged for OSA patients who can manage it comfortably. The hose management that makes side-sleeping comfortable is straightforward: modern hoses connect at the top of the mask (not the front), allowing free movement in both lateral positions. Specialist hose holders and mask designs are available specifically to make side-sleeping more comfortable if the standard setup is awkward.

The AHI categories (mild: 5–15, moderate: 15–30, severe: above 30) are clinical classification tools, not a direct measure of how significantly the condition affects any individual. Some people with an AHI of 8 are profoundly symptomatic; others with an AHI of 22 have minimal daytime impact. The clinical decision about treatment should be based on the full picture — symptom burden, cardiovascular risk profile, occupation (particularly if driving) and quality of life — not on the AHI category alone. Even mild OSA is associated with elevated cardiovascular risk over time, and the cumulative effect of years of mildly disrupted sleep architecture is not trivial. The conversation about whether treatment is warranted for mild OSA belongs with your sleep specialist, not with an assumption based on the category label.

NHS sleep services typically have a range of mask types available for trialling, including nasal pillow, nasal, and full face options across multiple brands and sizes. The initial mask you receive is a starting point, not a final allocation. If it is uncomfortable, ill-fitting, or causing you problems that are affecting your adherence, this is exactly the kind of problem your sleep clinic or NHS CPAP supplier exists to address. Many services have dedicated CPAP nurse or physiotherapist support specifically for remask appointments. If your current mask is a barrier to using CPAP consistently, contacting your sleep service to request a mask review is a reasonable and appropriate use of the service not a complaint or an imposition.

The evidence base for CPAP efficacy is extensive and spans multiple decades of randomised controlled trials and large cohort studies. CPAP consistently and reliably reduces AHI, reduces nocturnal oxygen desaturation, improves subjective sleep quality and daytime alertness, reduces blood pressure (particularly nocturnal blood pressure), reduces the risk of cardiovascular events in high-risk patients, and improves quality of life across validated outcome measures. The nuances exist: CPAP does not always normalise daytime sleepiness (because other sleep disorders may be co-present), and the cardiovascular benefits appear most pronounced in patients with significant baseline sleepiness or high cardiovascular risk. But the idea that CPAP merely changes numbers without producing clinical benefit is not supported by the evidence, and it is most commonly encountered as a rationalisation for not pursuing treatment rather than as a conclusion drawn from reviewing the data.

Obstructive sleep apnoea is associated in the research literature with significantly elevated risks of hypertension, atrial fibrillation, heart failure, stroke, type 2 diabetes, depression, and road traffic accidents. Each apnoea event produces a micro-stress response a surge of adrenaline and a spike in blood pressure as the brain forces an arousal to restore breathing. Repeated hundreds of times each night over months and years, this is not a trivial physiological burden. The condition is recognised by NICE, the British Thoracic Society, and every major respiratory and cardiovascular professional body as a clinically important diagnosis requiring treatment. The snoring is just the sound it makes the condition itself operates largely out of earshot, at a physiological level that explains why it took decades of research to fully characterise.